Business
Alkermes Announces Two Abstracts Accepted for Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
– Trial-in-Progress Posters From ARTISTRY-6 and ARTISTRY-7 Clinical Trials to be Presented – DUBLIN, May 9, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS)
About this update from Alkermes Plc
[{"type":"text","content":"– Trial-in-Progress Posters From ARTISTRY-6 and ARTISTRY-7 Clinical Trials to be Presented –\nDUBLIN, May 9, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the acceptance of two abstracts related to nemvaleukin alfa (nemvaleukin), the company's novel, investigational, engineered interleukin-2 (IL-2) variant immunotherapy, for presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place in Chicago June 2-6, 2023. Trial-in-progress posters from the actively recruiting phase 2 ARTISTRY-6 clinical trial and phase 3 ARTISTRY-7 clinical trial will be presented. ARTISTRY-6 is evaluating nemvaleukin as a monotherapy in patients with advanced cutaneous melanoma or advanced mucosal melanoma. ARTISTRY-7 is evaluating nemvaleukin as a monotherapy and in combination with pembrolizumab in comparison to investigator's choice chemotherapy in patients with platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer.\n\"The 2023 ASCO Annual Meeting provides a timely opportunity to engage with clinical trial investigators and share important information related to nemvaleukin and our potential registration-enabling clinical trials, ARTISTRY-6 and ARTISTRY-7,\" said Jessicca Rege, Vice President, Clinical Research, Oncology. \"Enrollment in both ARTISTRY-6 and ARTISTRY-7 is underway and we are excited to continue to accumulate data from these studies which we believe have potential to support registration in two difficult-to-treat tumor types.\"\nDetails of the poster presentations are as follows:\nAbstract: TPS9592Title: ARTISTRY-6: nemvaleukin alfa monotherapy in patients with advanced mucosal and cutaneous melanomaPresenter: Jeffrey S. Weber, Ph.D., M.D., Professor of Medicine, NYU School of Medicine and Deputy Director, Laura and Isaac Perlmutter Cancer CenterPresentation Date: The poster will be presented on Saturday, June 3, 2023 from 1:15 – 4:15 p.m. CDT, during the \"Melanoma/Skin Cancers\" poster session\nAbstract: TPS5612Title: ARTISTRY-7: a phase 3, multicenter study of nemvaleukin alfa in combination with pembrolizumab versus chemotherapy in patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer (GOG-3063; ENGOT-OV68)Presenter: Thomas J. Herzog, M.D., Professor of Obstetrics and Gynecology, Deputy Director, University of ...